UB Paderborn / Katalog / Suche / in CDI

1 – 24 von 24

Sortiert nach

Are endogenous sex hormones important for atherosclerotic cardiovascular disease risk in men?

Atherosclerosis, 2022-11, Vol.361, p.32-33

Reiner, Željko

2022

Link zum Volltext

Verfügbarkeit prüfen

PCSK9 inhibitors in clinical practice: Expectations and reality

Atherosclerosis, 2018-03, Vol.270, p.187-188

Reiner, Željko

2018

Link zum Volltext

Verfügbarkeit prüfen

Why might visit-to visit variability of lipoproteins have an effect on cardiovascular events?

Atherosclerosis, 2020-11, Vol.312, p.99-100

Reiner, Željko

2020

Link zum Volltext

Verfügbarkeit prüfen

Physicians’ perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: The PERCRO-DOC survey

Atherosclerosis, 2010-12, Vol.213 (2), p.598-603

2010

Link zum Volltext

Verfügbarkeit prüfen

Fetal toxicity associated with statins: A systematic review and meta-analysis

Atherosclerosis, 2021-06, Vol.327, p.59-67

2021

Link zum Volltext

Verfügbarkeit prüfen

Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology

Atherosclerosis, 2015-07, Vol.241 (1), p.169-175

2015

Link zum Volltext

Verfügbarkeit prüfen

Lysosomal acid lipase deficiency – An under-recognized cause of dyslipidaemia and liver dysfunction

Atherosclerosis, 2014-07, Vol.235 (1), p.21-30

2014

Link zum Volltext

Verfügbarkeit prüfen

Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: Findings from the EUROASPIRE III survey

Atherosclerosis, 2013-12, Vol.231 (2), p.300-307

2013

Link zum Volltext

Verfügbarkeit prüfen

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)

Atherosclerosis, 2012-07, Vol.223 (1), p.1-68

2012

Link zum Volltext

Verfügbarkeit prüfen

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

Atherosclerosis, 2011-07, Vol.217 Suppl 1 (1), p.S1-44

2011

Link zum Volltext

Verfügbarkeit prüfen

Comment to the position paper on global recommendations for the management of dyslipidemia developed by the International Atherosclerosis Society (IAS)

Atherosclerosis, 2014-04, Vol.233 (2), p.508-509

2014

Link zum Volltext

Verfügbarkeit prüfen

ESC/EAS Guidelines for the management of dyslipidaemias

Atherosclerosis, 2011-07, Vol.217, p.1-44

2011

Link zum Volltext

Verfügbarkeit prüfen

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

Atherosclerosis, 2016-10, Vol.253, p.281-344

2016

Link zum Volltext

Verfügbarkeit prüfen

Effect of simvastatin on micropulmonary red cell mass in patients with hyperlipoproteinemia

Atherosclerosis, 2001-02, Vol.154 (2), p.493-496

2001

Link zum Volltext

Verfügbarkeit prüfen

Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force

Atherosclerosis, 2021-05, Vol.325, p.99-109

2021

Link zum Volltext

Verfügbarkeit prüfen

ESC/EAS Guidelines for the management of dyslipidaemias

Atherosclerosis, 2011-07, Vol.217 (1), p.3-46

2011

Link zum Volltext

Verfügbarkeit prüfen

European guidelines on cardiovascular disease prevention in clinical practice: Executive summary

Atherosclerosis, 2007-09, Vol.194 (1), p.1-45

Graham, Ian

2007

Link zum Volltext

Verfügbarkeit prüfen

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)

Atherosclerosis, 2012, Vol.223 (1), p.1

2012

Link zum Volltext

Verfügbarkeit prüfen

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)t

Atherosclerosis, 2012, Vol.223 (1), p.1-68

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 24 von 24

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieAtherosclerosis

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(24)

Sprache

Englisch
(24)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(24)
EZB Free E-Journals
(24)
Ingenta
(24)
Elsevier ScienceDirect Journals Complete
(24)
IngentaConnect Journals
(10)

Menü

Weitere Dienste

Einstellungen

Are endogenous sex hormones important for atherosclerotic cardiovascular disease risk in men?

PCSK9 inhibitors in clinical practice: Expectations and reality

Why might visit-to visit variability of lipoproteins have an effect on cardiovascular events?

Physicians’ perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: The PERCRO-DOC survey

Fetal toxicity associated with statins: A systematic review and meta-analysis

Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology

Lysosomal acid lipase deficiency – An under-recognized cause of dyslipidaemia and liver dysfunction

ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: Findings from the EUROASPIRE III survey

Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an “FCS score”

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

Preclinical atherosclerosis and cardiovascular events: Do we have a consensus about the role of preclinical atherosclerosis in the prediction of cardiovascular events?

Comment to the position paper on global recommendations for the management of dyslipidemia developed by the International Atherosclerosis Society (IAS)

ESC/EAS Guidelines for the management of dyslipidaemias

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

Effect of simvastatin on micropulmonary red cell mass in patients with hyperlipoproteinemia

Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)

ESC/EAS Guidelines for the management of dyslipidaemias

European guidelines on cardiovascular disease prevention in clinical practice: Executive summary

Aktive Filter

Suchergebnisse filtern